The panel recommended the drug's approval with a 20-2 vote in February, after Vivus proposed a risk management program to limit Qsymia's distribution and published additional results from one of its three clinical trials.
As banks conserve cash, limit expansion and revamp broken risk-management processes, they face another mammoth task: rebuilding relationships with corporate clients.